Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate Bendall

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
BMC Cancer|August 24, 2012
Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practiceDerek Weycker, Aurelie Danel, Anne Marciniak, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2025
Tracking a Medicine's Regulatory Risk Management Commitments Provides Better Transparency and OversightSimon Ingate, Kate Bendall, Christopher Long, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 9, 2012
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimensPieternella Lugtenburg, Antonio Salar Silvestre, Francesca G Rossi, et al.
Breast (Edinburgh, Scotland)|January 24, 2016
The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid studyJohanna Mäenpää, Ioannis Varthalitis, Frans Erdkamp, et al.
Leukemia Research|March 6, 2012
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practiceAntonio Salar, Corinne Haioun, Francesca G Rossi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 22, 2011
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaRuth Pettengell, Hans E Johnsen, Hans E Johnson, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
BMC Cancer|August 24, 2012
Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practiceDerek Weycker, Aurelie Danel, Anne Marciniak, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2025
Tracking a Medicine's Regulatory Risk Management Commitments Provides Better Transparency and OversightSimon Ingate, Kate Bendall, Christopher Long, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 9, 2012
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimensPieternella Lugtenburg, Antonio Salar Silvestre, Francesca G Rossi, et al.
Breast (Edinburgh, Scotland)|January 24, 2016
The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid studyJohanna Mäenpää, Ioannis Varthalitis, Frans Erdkamp, et al.
Leukemia Research|March 6, 2012
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practiceAntonio Salar, Corinne Haioun, Francesca G Rossi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 22, 2011
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaRuth Pettengell, Hans E Johnsen, Hans E Johnson, et al.
Pageof 1